sonja althammer on role of cd8 and pd-l1 biomarkers for immunotherapy in nsclc
Published 7 years ago • 358 plays • Length 1:04Download video MP4
Download video MP3
Similar videos
-
0:55
sonja althammer discusses a biomarker for durvalumab in lung cancer
-
1:03
dr. barbara j. gitlitz on why pd-l1 is not a good biomarker for immunotherapy in lung cancer
-
1:16
dr. suzanne l. topalian on pd-l1 and emerging biomarkers for immunotherapy
-
46:35
the role of immunotherapy in non small cell lung cancer nsclc
-
9:54
is the pd-l1 biomarker ready for prime time?
-
14:55
advances in diagnosing lung cancer
-
27:08
immunotherapy advances in small cell lung cancer
-
2:50
the latest in lung cancer treatment
-
4:37
emerging biomarkers in lung cancer
-
6:36
8 in 8 series: biomarker testing and neoadjuvant immunotherapy for resectable nsclc
-
1:15
exploring biomarkers for immunotherapy treatment in lung cancer
-
1:37
dr. ready on the benefit of pd-l1 inhibition in sclc
-
1:59
dr. david l. rimm on alternatives to pd-l1 to predict immunotherapy response in lung cancer
-
19:05
what we know about immunotherapy treatments for lung cancer
-
2:09
ros1 biomarker lung cancer: is immunotherapy an option?
-
26:13
immunotherapies in lung cancer | 2022 evolution conference
-
0:36
how immunotherapy works for lung cancer
-
5:47
pd-l1 testing in metastatic nsclc
-
0:52
dr. sonpavde on trials of immunotherapy in bladder cancer
-
3:26
what if i don't have a biomarker?
-
1:29
what is car t cell therapy?
-
2:36
pd-l1 status in second-line lung adenocarcinoma